NCT01728454View on ClinicalTrials.gov

Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 2, 2013

Primary Completion Date

March 15, 2017

Study Completion Date

March 15, 2017

Conditions

Endometriosis

Interventions

DRUG

Placebo

Placebo matching capsules, orally, once daily for 18 weeks.

DRUG

Telapristone acetate

Telapristone acetate capsules, orally once daily for 18 weeks.

Trial Locations (10)

23235

Richmond

29485

Summerville

32258

Jacksonville

33063

Margate

70001

Metairie

72205

Little Rock

77030

Houston

84065

Riverton

84124

Salt Lake City

85712

Tucson

All Listed Sponsors

lead

Repros Therapeutics Inc.

INDUSTRY

NCT01728454 - Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis | Biotech Hunter | Biotech Hunter